Naproxen
Brand names: Naprosyn, Feminax Ultra
Naproxen is a non-steroidal anti-inflammatory drug (NSAID) used for pain, inflammation and gout; in older people it carries heightened gastrointestinal, renal and cardiovascular risks.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits cyclo-oxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and thereby decreasing pain and inflammation.
Prescribing in practice
- In older patients the gastrointestinal bleeding, renal and cardiovascular risks are increased, so use the lowest effective dose for the shortest time and consider gastroprotection, particularly with other risk factors.
- Avoid or use caution with anticoagulants, antiplatelets, ACE inhibitors/ARBs and diuretics, and in heart failure, peptic ulcer disease or significant renal impairment.
- Among non-selective NSAIDs naproxen carries comparatively lower cardiovascular thrombotic risk, which may favour it when an NSAID is needed in a patient with cardiovascular concerns.
Monitoring
Monitor renal function and blood pressure, and remain alert for gastrointestinal symptoms, especially in dehydrated or polypharmacy patients.
Counselling the patient
- Take with or after food and report black stools, vomiting blood or persistent indigestion.
- Avoid combining with other anti-inflammatory painkillers, including over-the-counter products.
- Report ankle swelling, breathlessness or reduced urine output.
Evidence & guidelines
Cardiovascular safety meta-analyses indicate naproxen has a lower thrombotic risk than several other NSAIDs, while MHRA guidance reinforces gastrointestinal and renal caution in older adults.
Reference: NICE CG177 (Gout); NICE NG226 (Osteoarthritis); AGS Beers Criteria 2023; STOPP/START v3; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Vancomycin Dosing Calculator · Drug Dosing
- Phenytoin Correction for Albumin / Renal Failure · Drug Dosing
- Local Anaesthetic Maximum Dose Calculator · Drug Dosing
- Tisdale Risk Score for QT Prolongation · Arrhythmia
- Bazett Corrected QT Interval (QTc) Calculator · Arrhythmia
- DAPT Score for Dual Antiplatelet Therapy Duration · Antiplatelet Therapy
- Falls Assessment in Older Adults · NICE CG161 2013
- Delirium Outside ICU · NICE CG103
- Comprehensive Geriatric Assessment (CGA) · BGS / NICE
- Delirium Assessment and Management · NICE CG103 2010
- Frailty Recognition and Management · BGS Frailty Framework / NHS NHSE
- Polypharmacy and Medicines Optimisation · STOPP/START v2 2014 / NICE NG5